Skip to main content

Table 1 Characteristics of patients

From: Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation

Age at HSCT (median) 19-58 (28 years)
Sex, F/M 13/24
Diagnosis
AML 13
B-ALL 12
T-ALL 2
CML 2
SAA 3
HL 1
OMF 1
MDS 3
Treatment before HSCT
ANT 29
cranial RT (24 Gy) 14
mediastinal RT (24 Gy) 2
Conditioning regimen
BUCY2 15
TBI+CY 12
CY+ATG 1
BCNU+VP-16+ARAC+MEL 1
BU+FLU+CY 3
FLU+CY+ATG 2
BU+FLU+ATG 1
FLAMSA 2
  1. HSCT hematopoietic stem cell transplantation, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myeloid leukemia, SAA severe aplastic anemia, HL Hodgkin's lymphoma, OMF osteomyelofibrosis, MDS myelodysplastic syndrome, CY cyclophosphamide, BU busulphan, TBI total body irradiation, FLU fludarabine, ATG antithymocyte globulin, MEL melphalan, BCNU carmustine, VP-16 etoposide, ARAC cytosine arabinoside, FLAMSA fludarabine + cytosine arabinosid + TBI + CY + amsacrine was replaced by idarubicin, ANT anthracyclines